GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Selling, General, & Admin. Expense

Sorrento Therapeutics (LTS:0L85) Selling, General, & Admin. Expense : $193.54 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Sorrento Therapeutics's selling, general, & admin. expense for the three months ended in Jun. 2023 was $48.94 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2023 was $193.54 Mil.


Sorrento Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Sorrento Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Selling, General, & Admin. Expense Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.64 103.56 116.18 196.86 182.34

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.14 50.16 39.46 54.98 48.94

Competitive Comparison of Sorrento Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Sorrento Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Selling, General, & Admin. Expense falls into.



Sorrento Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $193.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sorrento Therapeutics  (LTS:0L85) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Sorrento Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Industry
Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines